Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

doi: 10.1177/20420188251407515

Figure Lengend Snippet: Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition from Dexcom G6 ® to Dexcom G7 ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.

Article Snippet: Participants were followed for a total of 3 months post-transition, with two scheduled visits: a baseline visit, coinciding with the switch from Dexcom G6 to Dexcom G7, and a final follow-up visit at 3 months.

Techniques:

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

doi: 10.1177/20420188251407515

Figure Lengend Snippet: Changes in glycemic metrics following the transition from Dexcom G6 ® to Dexcom G7 ® in participants with baseline TIR 70–180 <70%. Stacked bar graphs represent the percentage of time spent in different glycemic ranges at each time point, comparing retrospective data collected with Dexcom G6 (days −90, −30, and −14) and prospective data collected with Dexcom G7 (days +14, +30, and +90). Green: TIR 70–180 ; Yellow: TAR >180 ; Orange: TAR >250 ; Red: TBR <70 . Statistically significant improvements were observed in TIR 70–180 ( p = 0.007), TAR >250 ( p = 0.003), and total TAR >180 ( p = 0.024) at day +90 compared to baseline measurements. TAR, time above range; TBR, time below range; TIR, time in range between 70 and 180 mg/dL.

Article Snippet: Participants were followed for a total of 3 months post-transition, with two scheduled visits: a baseline visit, coinciding with the switch from Dexcom G6 to Dexcom G7, and a final follow-up visit at 3 months.

Techniques:

Journal: Chemical Reviews

Article Title: Emerging Trends in Cross-Coupling: Twelve-Electron-Based L 1 Pd(0) Catalysts, Their Mechanism of Action, and Selected Applications

doi: 10.1021/acs.chemrev.2c00204

Figure Lengend Snippet: Structures of the Pd(I) dimers, Pd 2 (μ-allyl)(L 2 ) (μ-Cl), with L = SPhos (top) and AmPhos (bottom). In the bottom structure, Pd(I) dimer formation is less favored based on a Pd–Pd–P bond angle of 168.8° (vs 154.7° for SPhos) and closest point of contact of the tert -butyl substituents of 5.626 Å (vs 3.922 Å for SPhos). Reproduced with permission from ref . Copyright 2015 American Chemical Society.

Article Snippet: Using SPhos G6, research groups at Cornell and BASF jointly demonstrated that the halide salt, formed as a byproduct in the cross-coupling reaction, causes the transmetalation step to be reversible, and leads to strong reaction inhibition in the case of (hetero)aryl iodides.

Techniques: